Canaccord Genuity Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $114

Benzinga Newsdesk www.benzinga.com Positive 86.3%

Neg 0% Neu 0% Pos 86.3%

Canaccord Genuity analyst Whitney Ijem maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $111 to $114.